Tumor antigens BFA4 and BCY1 for prevention and/or treatment of cancer

Details for Australian Patent Application No. 2010224381 (hide)

Owner Aventis Pasteur Inc.

Inventors Pedyczak, Artur; Lovitt, Corey; SinghSandhu, Devender; Radvanyi, Laszlo; Parrington, Mark; Berinstein, Neil; Gallichan, Scott

Agent Spruson & Ferguson

Pub. Number AU-B-2010224381

Parent 2003263767

Filing date 22 September 2010

Wipo publication date 14 October 2010

Acceptance publication date 18 August 2011

International Classifications

C12N 15/63 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using vectors

A61K 38/00 (2006.01) Medicinal preparations containing peptides

C07K 5/00 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

Event Publications

14 October 2010 Application Open to Public Inspection

  Published as AU-B-2010224381

14 October 2010 Complete Application Filed

18 August 2011 Application Accepted

  Published as AU-B-2010224381

15 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010224382-Prophylactic pretreatment with antioxidants

2010224380-Mold for actuation sled having a curved guide member